{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:02Z","timestamp":1792788062093,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cmet.2026.09.021","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:59:18Z","timestamp":1791428358000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial"],"prefix":"10.1016","author":[{"given":"Zhiguang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-076X","authenticated-orcid":false,"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Bay","family":"Simony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-7802","authenticated-orcid":false,"given":"Thomas","family":"Holst-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiru","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2026.09.021_bib1","article-title":"Chronicity of obesity and the importance of early treatment to reduce cardiometabolic risk and improve body composition","volume":"15","author":"Christensen","year":"2025","journal-title":"Obes. Pillars"},{"key":"10.1016\/j.cmet.2026.09.021_bib2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity Phenotypes, Diabetes, and Cardiovascular Diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.cmet.2026.09.021_bib3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/oby.24358","article-title":"Projecting Global Trends and Inequalities in Adult Overweight and Obesity, 2023-2040: Findings From the NCD-RisC Database","volume":"33","author":"Liu","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.cmet.2026.09.021_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.09.021_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0140-6736(25)00260-0","article-title":"Forecasting the global obesity epidemic through 2050","volume":"405","author":"S\u00f8rensen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.09.021_bib6","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","article-title":"National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.09.021_bib7","doi-asserted-by":"crossref","first-page":"e1089","DOI":"10.1016\/S2468-2667(24)00250-0","article-title":"Diabetes in China part 1: epidemiology and risk factors","volume":"9","author":"Xu","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.cmet.2026.09.021_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2026.09.021_bib9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 Receptor Agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.021_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2026.09.021_bib11","first-page":"e005729","article-title":"Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity","volume":"13","year":"2026","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.cmet.2026.09.021_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2026.09.021_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biom15030408","article-title":"Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss","volume":"15","author":"Reiss","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cmet.2026.09.021_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cmet.2026.09.021_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1095753","article-title":"Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity","volume":"14","author":"Zaffina","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.cmet.2026.09.021_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eprac.2023.12.010","article-title":"A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management","volume":"30","author":"Chetty","year":"2024","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.cmet.2026.09.021_bib17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/oby.23521","article-title":"Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy","volume":"30","author":"Malik","year":"2022","journal-title":"Obesity"},{"key":"10.1016\/j.cmet.2026.09.021_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.cmet.2026.09.021_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.021_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/dom.71327","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1\/GIP\/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a\/1b Study","author":"Yang","year":"2026","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.cmet.2026.09.021_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/00325481.2022.2051366","article-title":"What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review","volume":"134","author":"Horn","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.cmet.2026.09.021_bib22","first-page":"90","article-title":"Chinese Guidelines for the Clinical Management of Obesity (2024 Edition)","volume":"16","year":"2025","journal-title":"Medical Journal of Peking Union Medical College Hospital"},{"key":"10.1016\/j.cmet.2026.09.021_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cmet.2026.09.021_bib24","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2026.09.021_bib25","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMc2211120","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Venniyoor","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cmet.2026.09.021_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s44446-025-00038-y","article-title":"GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity","volume":"33","author":"Alharbi","year":"2025","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.cmet.2026.09.021_bib27","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.cmet.2026.09.021_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13030069","article-title":"Electrolyte Imbalances and Metabolic Emergencies in Obesity: Mechanisms and Clinical Implications","volume":"13","author":"Crintea","year":"2025","journal-title":"Diseases"},{"key":"10.1016\/j.cmet.2026.09.021_bib29","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2026.09.021_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11894-025-00995-3","article-title":"Gastrointestinal Motility Effects of GLP-1 Receptor Agonists","volume":"27","author":"Bellavance","year":"2025","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.cmet.2026.09.021_bib31","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab022","article-title":"Evidence for Glucagon Secretion and Function Within the Human Gut","volume":"162","author":"Sun","year":"2021","journal-title":"Endocrinology"}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413126004341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413126004341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:20:41Z","timestamp":1792786841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413126004341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S1550413126004341"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2026.09.021","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2026.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2026.10.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}